angiogenic factors induce CD13 expression in endothelial cells (Bhagwat et al. 2001; Mina Osorio 2008) ; finally, CD13null mice show reduced angiogenic responses to growth factors and are significantly deficient in promoting retinal neovascularization under hypoxic conditions (Rangel et al. 2007) . Overall, these data indicate that CD13 exerts key roles in angiogenesis.
It has recently been demonstrated that phages expressing the amino acid sequence Asp-Gly-Arg (NGR) can bind CD13 (Pasqualini and Ruoslahti 1996; Pasqualini et al. 2000; Arap et al. 2002) . Different CD13 forms are expressed within tumor vessels, normal epithelia, and myeloid cells , providing support for varying ligand specificities. Furthermore, the NGR motif can bind to vessels within or close to tumor nodules but not to vessels or epithelia in normal tissues (Curnis, Arrigoni, et al. 2002) . On the basis of these observations, it has been suggested that the tumor-homing properties of the NGR peptides rely on recognition of a CD13 form selectively expressed within tumor-associated vessels .
In this study, we investigated the expression of CD13 in several human tumor, inflammatory, and normal tissues using three different monoclonal antibodies (mAbs; WM15, BF10, 3D8). We show that the expression of CD13 is enhanced in the vasculature of most neoplastic tissues, of some inflammatory lesions, whereas it is almost undetectable in the vasculature of most normal tissues.
Material and Methods Tissues
Unfixed surgical specimens from different organs and skin biopsies were rapidly sent to our pathology department. Upon gross examination, either nonneoplastic or neoplastic areas from the same specimen were separately collected, snap frozen, and stored at −70C. Frozen sections (3-5 µm) were air dried for 30 min and fixed with paraformaldehyde for 20 min at 4C. Specimens analyzed included 239 human specimens (frozen sections), represented by 58 normal, 32 inflammatory, and 149 tumor tissues (Tables 1-3) . For each case, diagnosis was established on routine paraffin-embedded material according to standard histopathologic criteria. Protocols for taking the specimens from patients have been performed in accordance with the Helsinki Declaration of 1975 and the San Raffaele Hospital Review Board.
Immunohistochemistry Procedure
Immunohistochemical analysis was performed with the following three anti-CD13 mAbs: WM15 (1:5000, mouse IgG 1 κ; BD Pharmingen, Franklin Lakes, NJ), 3D8 (1:100, mouse IgG 1 κ; Thermo Scientific, Waltham, MA), and BF10 (1:100, mouse IgG 1 κ; Thermo Scientific). WM15 recognizes an epitope in the vicinity of the catalytic site, whereas 3D8 recognizes a different epitope lying outside the catalytic site (Ashmun et al. 1992) ; the BF10 epitope is unknown. Unlike WM15, BF10 and 3D8 can be used in Western blot analysis. The epitope recognized by WM15 is destroyed during the process of formalin fixation and paraffin embedding. Therefore, we performed all immunostainings with the three mAbs using frozen sections. Finally, the three mAbs have been raised against different tumor cells (mAb data sheets). Detection was performed with Super Sensitive Polymer-HRP IHC Detection Systems (Biogenex, San Ramon, CA), according to the manufacturer's instructions, followed by chromogenic reaction with diaminobenzidine (DAB chromogen, cod. K3468; DakoCytomation, Fort Collins, CO); the slides were counterstained with Harris hematoxylin for 10″. Negative controls were performed by omitting the primary antibody. The immunostaining of each tissue was evaluated independently by two of us (G.L.A. and P.D.M.), and consensus was reached for discordant cases. We semiquantitatively defined the grading as follows: >80% (+++), 40-80% (++), 10-40% (+), <10% (+/−) positive cells; no staining (-). In the summary tables (Tables 1-3) , the immunostaining "+", "++," and "+++" were considered positive, whereas the staining "+/−" and "-" were considered negative.
Immunofluorescence Staining
To demonstrate co-localization between CD13 and vessels, selected samples were stained with anti-CD13 and anti-CD31 by immunofluorescence. Frozen sections were blocked with 1% bovine serum albumin and 5% fetal bovine serum (FBS). Sections were then stained with the following antibodies: anti-CD13, WM15-Alexa Fluor 488 (mouse IgG   1 ; Axxora, Lausen, Switzerland), and anti-CD31 (rabbit polyclonal; Thermo Scientific) antibody followed by anti-rabbit AlexaFluor 555-conjugated antibodies (Invitrogen, Carlsbad, CA). The results were observed, and the images were captured with a Nikon 80iEclipse fluorescent microscope.
Flow Cytometry
Flow cytometry analysis (FACSCalibur; BD Biosciences, Franklin Lakes, NJ) was performed on CD31 + CD45 − endothelial cells identified with mouse anti-human FITC-CD31 (IgG 1 κ, clone WM59; BD Biosciences) and mouse antihuman PerCP-CD45 (IgG 1 κ, clone 2D1; BD Biosciences) mAbs in homogenized human tissue specimens of paired normal colon and colon adenocarcinoma (n = 2) and on endothelial cells isolated from the vein of the umbilical cord (human umbilical vein endothelial cells [HUVEC]; PromoCell, Heidelberg, Germany).
Immediately after sampling, fresh normal colon and colon adenocarcinoma tissue specimens were homogenized with a 1-mg/ml mix of A and B collagenases (Roche, Basel, Switzerland) for 90 min at 37C, followed by mechanic cellularization and 40µ filtration. Cells (5-10 × 10 5 ) were then washed twice in PBS with 2% FBS and incubated with anti-CD31, anti-CD45, and the three anti-CD13 mAbs (WM15, BF10, and 3D8) for 30 min at 4C. After washing twice, cells stained with the anti-CD13 mAbs were incubated with a goat F(ab′)2 anti-mouse PE-conjugated IgG (Southern Biotech, Birmingham, AL) for 30 min at 4C; after washing twice, cells were finally suspended in PBS with 2% FBS for analysis (FlowJo Software, version 7.2.2; Tree Star Inc., Ashland, OR). To obtain a reliable CD31 + CD45 − population gating, at least 5 × 10 5 cells were acquired for analysis. Activated exponentially growing HUVEC (2 × 10 5 ) were detached with trypsin/EDTA, centrifuged at 1200 rpm for 5 min, and then incubated with either mouse anti-human AlexaFluor 488-endoglin (CD105, IgG 1 , clone SN6; Serotec, Kidlington, UK) or anti-CD13 mAbs, testing each of the three clones (WM15, BF10, and 3D8), as above described.
Results

Tumor Tissues
Immunohistochemical analysis with WM15, BF10, and 3D8 mAbs was performed on 149 cases of different tumors (Table 1) . Results are detailed below considering the three main neoplastic tissue components: tumor vessels, tumor stroma, and neoplastic cells. In addition, the three mAbs were tested in endothelial cells of two colon adenocarcinoma fresh tissue samples using flow cytometry.
CD13 expression in tumor vessels. WM15, BF10, and 3D8 mAbs detected CD13 in almost all vessels in tumor tissues (WM15, 99/101, 98.0%; BF10, 24/24, 100%; 3D8, 23/24, 95.8%). WM15 revealed almost all capillaries in tumor tissues, whereas arteries and venules were only occasionally decorated. In particular, it bound small intratumor and peritumor vessels of bowel (12/13) and pancreas (13/13) adenocarcinomas, breast carcinomas (12/12), lung squamocellular carcinomas (8/8), renal cell carcinomas (18/19), papillary carcinoma of thyroid (1/1), soft tissue tumors (7/7), and glioblastoma (1/1) specimens ( Figure 1 ). WM15 did not stain tumor vasculature in only two cases: one colon adenocarcinoma and one renal cell carcinoma.
The immunoreactivity of BF10 and 3D8 was quite different: They reacted with endothelia of large vessels and only partially with capillaries. In addition, the signal produced by BF10 was often more intense and often less specific for intratumor and peritumor vessels than that produced by WM15. In particular, BF10 detected almost all vessels in gastric (3/3), bowel (3/3), and pancreas (2/2) adenocarcinomas; mesothelioma (1/1); soft tissue tumors (10/10); and glioblastoma (1/1) specimens (Figure 1) . Although the staining patterns of BF10 and 3D8 were similar in most tissues, the intensity of 3D8 staining was weaker than that of BF10. In particular, 3D8 immunorevealed tumor large vessels in colon (3/3) and gastric In both tumor histotypes, the three mAbs stained stroma and tumor vessels, with WM15 preferentially highlighting small tumor vessels.
(3/3) adenocarcinomas, glioblastoma (2/2), and soft tissue tumors (10/10). Differently from BF10, 3D8 did not detect tumor vasculature in mesothelioma specimen. Finally, the three mAbs stained CD31 + CD45 − endothelial cells obtained homogenizing fresh colon adenocarcinoma tissue samples, and WM15 showed the highest median fluorescence intensity (MFI; Figure 2 ).
CD13 expression in tumor stroma. All three antibodies immunorevealed the tumor stroma in about half of neoplastic tissues (WM15, 59/101, 58.4%; BF10, 15/24, 62.5%; 3D8, 12/24, 50.0%). In particular, WM15 diffusely stained fibroblasts and connective tissue in hepatocarcinoma (9/11), colorectal (12/13), and pancreas (8/8) adenocarcinoma; lung adenocarcinoma (7/7); and squamocellular carcinoma (8/8) specimens (Figure 1 ). With a staining pattern similar to that of WM15, BF10 and 3D8 decorated connective tissues in colon and pancreas adenocarcinoma, mesothelioma, osteosarcoma, and thyroid papillary carcinoma specimens (Figure 1) .
CD13 Expression in Neoplastic Cells. The three antibodies immunorevealed some tumor cell types (WM15 24/101, 23.8%; BF10 6/24, 25.0%; 3D8 5/24, 20.8%). In particular, WM15 stained tumor cells in kidney carcinoma (14/17), mesothelioma (1/1; Figure 3A , B), hepatocarcinoma (2/2; Figure 3C , D), gastric adenocarcinoma (3/3), and thyroid papillary carcinoma (1/1). Likewise, BF10 and 3D8 stained neoplastic cells in gastric adenocarcinoma, (3/3), mesothelioma (1/1), and in thyroid papillary carcinoma (1/1); BF10 also stained cancer cells of pancreas adenocarcinoma (1/1). CD13 (WM15) and CD31 localization in tumor vessels. To establish the exact localization of CD13 in tumor endothelial cells, an immunofluorescence staining was performed with WM15 and CD31 antibodies. As shown in Figure 3E , both CD31 and WM15 stained tumor endothelial cells; however, with different patterns. CD31 bound to the luminal border of tumor blood vessels, whereas WM15 preferentially stained the extraluminal border of endothelial cells and some auxiliary cells, like pericytes.
Inflammatory Lesions
The immunoreactivity of WM15, BF10, and 3D8 mAbs with vessels, stroma, and parenchyma was also investigated in 32 inflammatory lesions (Table 2) .
CD13 expression in inflammation-associated vessels. The three antibodies stained vessels in about half of inflammatory lesions (WM15 6/8, 75.0%; BF10 5/12, 41.7%; 3D8 5/12, 41.7%). In particular, WM15 decorated capillaries and only partially large vessels in 5/7 inflammatory skin and 1/1 tonsil sections. BF10 and 3D8 produced almost identical results, staining vessels of dermo-epidermal junction in 4/11 inflamed skin and 1/1 tonsil sections (Figure 4) .
CD13 expression in stroma. WM15 stained stroma of 5/7 inflamed skin and 1/1 tonsil sections, whereas BF10 and 3D8 immunorevealed fibroblasts and connective tissues in 8/11 inflammatory skin and 1/1 tonsil specimens.
CD13 expression in inflammatory cells and epithelia. WM15, BF10, and 3D8 neither stained epithelia nor lymphoid population in all inflammatory lesions tested. Of note, all antibodies weakly and occasionally immunorevealed inflammatory cells (macrophages, dendritic cells, whereas lymphocytes resulted always negative), as expected.
Normal Tissues
We investigated the immunoreactivity of WM15, BF10, and 3D8 mAbs also in 58 normal tissue samples (Table 3 ). In addition, the three mAbs were tested in endothelial cells of two normal colon fresh tissue samples and in HUVEC using flow cytometry. CD13 expression in vessels. The antibodies stained blood vessels in a small percentage of normal tissues (WM15 3/32, 9.3%; BF10 4/13, 30.7%; 3D8 4/13, 30.7%; Figure 5 ). Of note, WM15 stained blood vessels in only 3/32 cases: in particular, WM15 stained sinusoids of 3/7 liver sections while neither stained centrolobular vein nor veins and arteries of portal space. Likewise, 3D8 and BF10 decorated only a small percentage of blood vessels (BF10 4/13, 3D8 4/13; : WM15 (A, B) , BF10 (C, D), and 3D8 (E, F). All mAbs stained stroma and vessels along with some inflammatory cells. Figure 5) . At flow cytometry, the three mAbs failed to stain CD31 + CD45 − endothelial cells obtained homogenizing fresh normal colon tissue samples (Figure 2 ), whereas they stained HUVEC with a similar intensity (data not shown). This is not surprising because HUVEC were exponentially growing and activated, as indicated by their expression of endoglin/CD105 (data not shown).
CD13 expression in stroma. WM15 bound the stroma in 12 of 32 specimens (37.5%): six liver, five bowel (basal membrane, fibroblasts, and in particular pericryptal fibroblasts), and one lung (connectival septs) specimen. BF10 and 3D8 stained stroma in liver, pancreas, and bowel specimens.
CD13 expression in epithelia. WM15 immunoreacted with normal epithelial cells in liver (hepatocytes and biliary ducts) and kidney (proximal tubules and Bowman capsule) specimens. Weak and variable staining was observed on the luminal border of gastrointestinal, mammary, and bronchial epithelia. Both BF10 and 3D8 stained liver and bowel epithelium, whereas only BF10 stained acinar structure and ducts of pancreas and the epithelium of stomach. Pancreatic endocrine cells were negative. All antibodies occasionally stained macrophages and dendritic cells present in the tissue specimens, as expected.
Discussion
Several studies investigated the expression of CD13 in various tissues using different mAbs obtaining varying results (Palmieri et al. 1985; Drexler 1987; Look et al. 1989; Ashmun and Look 1990; Ashmun et al. 1992; Kunz et al. 1994; Riemann et al. 1999 ). Among these, some reports showed that different anti-CD13 antibodies can recognize diverse forms of CD13 in normal epithelial cells, tumor-associated vessels, and myeloid cells Pasqualini et al. 2000) . The structural determinants responsible for differential binding of anti-CD13 antibodies to CD13 are still unclear. It has been suggested that differential O-glycosylation generates at least five forms of CD13 that are variably recognized by antibodies, likely because of diverse masking of protein epitopes (O'Connel et al. 1991) . In addition, CD13 may undergo posttranslational modifications in tumor cells that may uncover an epitope, which can be recognized by specific mAbs, which is masked in normal tissues.
In the present study, we observed that although all antibodies tested, including WM15, 3D8, and BF10, stained vessels in most neoplastic tissues and tumor stroma in about half of the samples, the pattern of reactivity significantly varied among them, particularly between WM15 on one hand and BF10 and 3D8 on the other hand. As a matter of fact, WM15 immunodetected almost all intratumor and peritumor capillaries, whereas it only occasionally detected arteries and venules. This antibody also stained tumor cells of some histotypes, consistent with previous reports showing CD13 expression in non-small-cell lung cancer (Ito al. 2009 ) and in hepatocellular (Rocken et al. 2005) , ovarian (Surowiak et al. 2006; Terauchi et al. 2007 ), gastric (Kawamura et al. 2007) , and pancreatic carcinomas (Ikeda et al. 2003) . At variance, the immunoreactivity of BF10 and 3D8 significantly differed from that of WM15. First, the signal produced by BF10 was always more intense but less restricted to tumor vessels than that produced by WM15. Although the staining patterns of BF10 and 3D8 were similar in most tissues, the intensity of BF10 staining was greater than that of 3D8. Second, both BF10 and 3D8 bound to the endothelium of almost all arteries and venules and only partially to that of tumor capillaries. In agreement with these data, the three mAbs stained CD31 + CD45 − endothelial cells of colon adenocarcinoma tissue specimens. Considering that conceivably, these tumor samples contained more capillaries than arteries and venules, it is interesting to note that the CD13 MFI was higher with WM15 than using BF10 and 3D8, consistent with the different preferential staining of WM15 for tumor capillaries.
Different results were obtained with inflammatory lesions, as in this case the three antibodies stained vessels in only half of the tissues tested. Nevertheless, WM15, BF10, and 3D8 stained the stroma, and again, WM15 was more selective for capillaries, whereas BF10 and 3D8 reacted with large vessels and only partially with capillaries.
Of note, in normal tissues, the three antibodies stained only a small percentage of blood vessels (WM15: 9.3%; BF10: 30.7%; 3D8: 30.7%). A higher percentage value of reactivity (~50%) was present in liver vessels, conceivably due to the peculiar anatomic and functional characteristics of the sinusoidal endothelium and pericytes/hepatic stellate cells, which have unique regenerative potential and scavenger activity (Enomoto et al. 2004; Lee et al. 2007 ). Furthermore, these antibodies stained monocytes/macrophages, biliary ducts, kidney proximal tubules, and luminal surface of intestinal epithelia although to a different extent (WM15 34.4%; BF10 76.9%; 3D8 61.5%). Of note, only BF10 stained acinar and ductal cells of pancreas. These results on normal tissues are in line with those of previous reports (Ashmun and Look 1990; Taylor 1993; Dixon et al. 1994; Piela-Smith and Korn 1995; Riemann et al. 1997; Riemann et al. 1999; Bauvois and Dauzonne 2006) . Overall, our results provide support for the concept that different immunoreactive forms of CD13 are present in different tissues in normal and pathological conditions. Remarkably, they also indicate that CD13 is expressed by vessels in neoplastic and some inflammatory lesions, with minimal reactivity in the vasculature of normal tissues.
Previous studies investigated the role of CD13 in tumors. Some papers suggested that CD13 could be exploited as a diagnostic and prognostic marker in certain tumors, such as lung squamous cell carcinoma and other non-small-cell lung cancer, gastric and colon carcinoma, hepatocellular and pancreatic carcinoma, ovarian and cervical cancer (Hashida et al. 2002; Ikeda et al. 2003; Rocken et al. 2005; Ichimura et al. 2006; Surowiak et al. 2006; Tokuhara et al. 2006; Kawamura et al. 2007; Terauchi et al. 2007; Yamashita et al. 2007; Tsukamoto 2008; Ito et al. 2009 ). More recently, other papers showed that CD13 plays multiple roles in angiogenesis (Pasqualini et al. 2000; Bhagwat et al. 2001; Bhagwat et al. 2003; Bauvois 2004; Bauvois and Dauzonne 2006; Fukasawa et al. 2006; Mahoney et al. 2007; Rangel et al. 2007; Yang et al. 2007; Mina Osorio 2008) . Consistently, we observed that angiogenic/activated (CD105 + ) exponentially growing HUVEC overexpressed CD13 and stained positive to the three anti-CD13 mAbs (data not shown), which in contrast did not stain CD31 + CD45 − endothelial cells obtained homogenizing fresh normal colon tissue samples. In addition, it has been reported that CD13 is critical for the development of new blood vessels from existing vessels in pathological conditions (Rangel et al. 2007 ). Consistently, we demonstrated that CD13 is diffusely expressed in tumor vasculature and stroma and, in particular, that tumor capillaries-conceivably angiogenic onesare efficiently recognized by WM15 and to a much lesser extent by BF10 and 3D8. Overall, these findings indicate that CD13 is up-regulated during angiogenesis, including the one occurring during inflammation and tumor growth, and that WM15 is selective for a CD13 form expressed by mostly angiogenic tumor neovasculature (i.e., tumor capillaries).
The enhanced expression of CD13 in vessels of pathologic tissues could have important implications for therapies based on CD13-positive vessel targeting (Arap et al. 1998a; Corti 2004; Corti and Ponzoni 2004) , in particular for those based on the use of the NGR peptide as a CD13targeting ligand (Curnis, Arrigoni, et al. 2002; Pasqualini et al. 2000) . This peptide has been used for delivering various antitumor compounds, such as chemotherapeutic drugs, apoptotic peptides, viral particles, cytokines (Gregorc et al. 2009; Gregorc, Zucali, et al. 2010; Santoro, Pressiani, et al. 2010; van Laarhoven et al. 2010) , and liposomes, to tumor vessels (Arap et al. 1998a (Arap et al. , 1998b Ellerby et al. 1999; Curnis et al. 2000; Liu et al. 2000; Grifman et al. 2001; Pastorino et al. 2003; Curnis et al. 2005; Garde et al. 2007 ). Among these, NGR-hTNF (www.molmed.com), which couples CNGRCG with hTNFα, is currently tested in phase 2 and 3 clinical trials (Gregorc et al. 2009; Gregorc, Zucali, et al. 2010; Santoro, Pressiani, et al. 2010; van Laarhoven et al. 2010) . Our finding that CD13 is expressed in the vasculature of most of the tumors tested, but not of normal tissues, suggests that NGR-peptide conjugates could potentially target the vasculature of most solid tumors.
Although CD13 is expressed also by many normal cell types and tissues, such as biliary ducts, kidney proximal tubules, luminal surface of intestinal epithelia (Atherton et al. 1992; Taylor 1993; Dixon et al. 1994; Chen et al. 1996; Bogenrieder et al. 1997; Riemann et al. 1999) , previous papers demonstrated that the NGR peptide can selectively bind a form expressed by the tumor vasculature Pasqualini et al. 2000) . Remarkably, the finding that CD13 is expressed also both in the vasculature of some inflammatory skins and tonsils and in angiogenic/activated HUVEC indicates that the vascular expression of CD13 may not be limited to tumors. Whether this form of CD13 is recognized by NGR peptides remains to be investigated.
In conclusion, although all antibodies tested in this study bind tumor vessels, WM15 binds almost all tumor capillaries and little or no large vessels, whereas BF10 and 3D8 bind large peritumor vessels and much less small vessels. Therefore, WM15 may be a good tool for detecting the CD13 form associated with the angiogenic tumor vasculature. This finding may be relevant for CD13-mediated vascular targeting therapies.
